PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Theralase Technologies Inc.

USPTO PatentsView assignee record - 9 granted patents across 5 technology areas, recorded in grant years 2017–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy).

RSS updates for this company
Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Theralase ranks #30,404 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 5 technology areas.

#30,404
of 49,997 US assignees by volume
Top 36%
by Innovation Score (40.1/100)
18.2
avg claims per patent
+67%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R30404 · Foreign Corporation #30,404 · 9 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

  • GRANTS-MICRO 9 grants
  • MID-PACK #30,404/49,997
  • PHOTO-FINISH The SkyLife
  • CPC-NARROW A61N · 5 areas
  • INNOV-PAR 40.1/100
  • CLAIMS-RICH 18.2 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-SURGE +67% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: The SkyLife Company, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Theralase’s 40.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Theralase

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Theralase's Innovation Score is 40.1/100 (top 36% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Theralase?

Each dot is one of Theralase’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Theralase’s own 18.2 claims/patent is ABOVE the 14.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Theralase vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 8.98.999.1 0102030 Granted patents (volume) Avg claims / patent The SkyLife Company, Inc. - 9, 14.67The SkylifeThe Steel Network, Inc. - 9, 11.89The Steel NetworkThe Tin Box Company of America, Inc. - 9, 1The Tin Box of Am…The University of The West Indies - 9, 16.56The University of…Thermatool Corp. - 9, 17.89ThermatoolThermoteknix Systems Ltd. - 9, 24.11Thermoteknix Syst…Think Tank Photo, Inc. - 9, 9.11Think Tank PhotoThromboGenics NV - 9, 28.11ThrombogenicsTheralase Technologies Inc. - 9, 18.22Theralase
Theralase vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Theralase's grants concentrate

Theralase Technologies Inc. is a focused PatentsView assignee: 5 CPC subclasses with 77.8% of grants classified under A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy). Peak complete grant year is 2022 (2 grants) versus a trough of 1 in 2017. By volume, Theralase sits between The SkyLife Company, Inc. and ThromboGenics NV.

Theralase's three-year grant acceleration

Theralase Technologies Inc. shows 4 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Theralase's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Theralase holds 9 patents at rank #30,405, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Theralase

By rank, the assignees closest to #30,405 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in Theralase's primary technology class.

Theralase's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

40 Top 36% higher than 64% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.5 2017201820192020202220232025 1
USPTO utility patent grants by year · 2017–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table
Theralase Technologies Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2017 1 11.1%
2018 1 11.1%
2019 1 11.1%
2020 1 11.1%
2022 2 22.2%
2023 2 22.2%
2025partial year 1 11.1%

Which technologies does Theralase Technologies Inc. patent most?

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Theralase Technologies Inc.'s patent record in context - here's where to go next.

  • Theralase Technologies Inc.'s lead technology class is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy), 77.8% of its portfolio - see every assignee active in that class. Explore A61N
  • Ranked #30,404 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Theralase Technologies Inc. against The SkyLife Company, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 40.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.